Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 4.31B +501.6% |
| Revenue (ttm) | n/a |
| Net Income | -152.09M |
| EPS | -1.43 |
| Shares Out | 111.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,644,894 |
| Open | 39.80 |
| Previous Close | 39.66 |
| Day's Range | 38.35 - 41.14 |
| 52-Week Range | 7.96 - 41.14 |
| Beta | -0.20 |
| Analysts | Strong Buy |
| Price Target | 42.18 (+9.11%) |
| Earnings Date | Aug 6, 2026 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $42.18, which is an increase of 9.11% from the latest price.
News
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,00...
Amylyx price target raised to $42 from $30 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx (AMLX) to $42 from $30 and keeps an Outperform rating on the shares. The firm citers the positive results…
Amylyx price target raised to $55 from $40 at Guggenheim
Guggenheim raised the firm’s price target on Amylyx (AMLX) to $55 from $40 and keeps a Buy rating on the shares. Avexitide’s striking efficacy and tolerability support strong uptake across…
Amylyx price target raised to $52 from $28 at Baird
Baird raised the firm’s price target on Amylyx (AMLX) to $52 from $28 and keeps an Outperform rating on the shares. The firm updated its model following its clear win…
Amylyx price target raised to $39 from $30 at BofA
Amylyx’s (AMLX) raised the firm’s price target on Bank of America to $39 from $30 and keeps a Buy rating on the shares. Amylyx’s positive Phase 3 LUCIDITY results validate…
Amylyx announces $350M common stock offering
Amylyx (AMLX) Pharmaceuticals announced that it has commenced an underwritten public offering of $350M of shares of its common stock. All of the shares of common stock are being offered…
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 mil...
Amylyx stock soars on GLP-1 success: here's why investors should sell
Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluate...
Amylyx price target raised to $52 from $28 at Baird
Baird raised the firm’s price target on Amylyx (AMLX) to $52 from $28 and keeps an Outperform rating on the shares.
Amylyx price target raised to $55 from $34 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Amylyx (AMLX) to $55 from $34 and keeps a Buy rating on the shares. Amylyx’s positive LUCIDITY results substantially de-risk avexitide, with…
Amylyx price target raised to $45 from $21 at Stifel
Stifel raised the firm’s price target on Amylyx (AMLX) to $45 from $21 and keeps a Buy rating on the shares. Avexitide’s best-case PBH topline data appear to substantially de-risk…
Amylyx Shares Jump 45% Following Positive Phase 3 Trial Results for GLP-1 Blocker Avexitide
Amylyx Pharmaceuticals ($AMLX) stock jumped 45% to $28.38 in early trading on Tuesday, August 18, after the company reported positive results from its pivotal Phase 3 LUCIDITY clinical trial. The…
Stifel views Amylyx data as ‘best-case scenario’
Stifel says Amylyx (AMLX)’ LUCIDITY results “look excellent.” Avexitide had a “clear win” on the primary endpoint and clean safety and tolerability, the analyst tells investors in a research note.
Amylyx Phase 3 data support FDA approval, says Citi
Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled trial evaluating the drug in participants with post-bar...
Amylyx up 28% at $27.50 after announcing Lucidity trial met primary endpoint
08:32 EDT Amylyx (AMLX) up 28% at $27.50 after announcing Lucidity trial met primary endpoint
Amylyx Pharmaceuticals Transcript: Study result
The phase III LUCIDITY trial showed avexitide significantly reduced hypoglycemic events in PBH patients after gastric bypass, meeting all primary and secondary endpoints with a favorable safety profile. The therapy addresses a major unmet need, with high patient and clinician enthusiasm, and is on track for NDA submission and potential U.S. launch in 2027.
Amylyx Pharmaceuticals Press release: Study result
Amylyx Pharmaceuticals issued a press release on August 18, 2026, disclosing material business information to investors.
Amylyx Pharmaceuticals Slides: Study result
Amylyx Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Amylyx Stock Surges 21% After GLP-1 Drug Succeeds in Phase 3 Trial
Amylyx Pharmaceuticals says its GLP-1 receptor antagonist, avexitide, met both the primary and secondary endpoints in a late-stage clinical trial.
Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial
Amylyx Pharmaceuticals said on Tuesday its experimental drug met its main goal in a late-stage trial for post-bariatric hypoglycemia, a condition marked by dangerously low blood sugar levels followi...
Amylyx announces Lucidity Phase 3 trial met primary endpoint
Amylyx (AMLX) Pharmaceutical announced topline results from Lucidity, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and saf...
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced positive topline results from LUCIDITY, a 78-participant, multicent...
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide...